Canbridge Pharmaceuticals (FRA:MF1) Cash per Share: €0.02 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MF1 Canbridge Pharmaceuticals Inc FRA:MF1
48 GF Score
Price €0.19
GF Value €0.04
! 6 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals Cash per Share?

Canbridge Pharmaceuticals FRA:MF1 -1.05% 48 Cash per Share is €0.02 as of Dec. 2025. GuruFocus rates FRA:MF1 with a GF Score™ of 48/100 and a GF Value™ of €0.04. The stock has 6 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Canbridge Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2025 was €0.02.

Canbridge Pharmaceuticals  (FRA:MF1) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Canbridge Pharmaceuticals Cash per Share Related Terms

Canbridge Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Canbridge Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals Cash per Share Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial 0.24 0.14 0.04 0.00 0.02

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.02 0.02
FRA:MF1
48GF Score
Canbridge Pharmaceuticals Inc FRA:MF1
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canbridge Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Canbridge Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=8.078/511.12
=0.02

Canbridge Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=8.078/511.12
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of €0.02 mean?
Canbridge Pharmaceuticals (FRA:MF1) has a Cash per Share of €0.02 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Canbridge Pharmaceuticals and its competitors.
Is Canbridge Pharmaceuticals' Cash per Share too high?
Canbridge Pharmaceuticals' current Cash per Share is €0.02. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Cash per Share compare to VRTX and REGN?
Canbridge Pharmaceuticals' Cash per Share of €0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Canbridge Pharmaceuticals and its competitors. Canbridge Pharmaceuticals's current Cash per Share is €0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current Cash per Share of €0.02. The stock's GF Value™ is €0.04, compared to a current price of €0.19 — trading 370% above its estimated fair value. The current Cash per Share is €0.02. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current Cash per Share is €0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of €0.19 is trading 370% above its estimated GF Value™ of €0.04.

Key valuation signals for FRA:MF1:

  • Cash per Share: €0.02
  • GF Value™: €0.04 vs. price of €0.19 (370% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Other Exchanges 01228:Hong Kong
Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score

Get the complete analysis for FRA:MF1

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.04
GF Value